Breakthrough Designation for Palbociclib (PD 0332991) for Breast Cancer

&NA;

Open source

DOI
10.1097/01.cot.0000430618.33439.69
Published
2013-05
Container
Oncology Times
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/01.cot.0000430618.33439.69,
  title = {Breakthrough Designation for Palbociclib (PD 0332991) for Breast Cancer},
  author = {\&NA;},
  year = {2013},
  journal = {Oncology Times},
  doi = {10.1097/01.cot.0000430618.33439.69},
  url = {https://doi.org/10.1097/01.cot.0000430618.33439.69}
}

RIS

TY  - JOUR
TI  - Breakthrough Designation for Palbociclib (PD 0332991) for Breast Cancer
AU  - &NA;
PY  - 2013
JO  - Oncology Times
DO  - 10.1097/01.cot.0000430618.33439.69
UR  - https://doi.org/10.1097/01.cot.0000430618.33439.69
ER  - 

APA

&NA; (2013). Breakthrough Designation for Palbociclib (PD 0332991) for Breast Cancer. Oncology Times. https://doi.org/10.1097/01.cot.0000430618.33439.69

Source records